RESUMEN
Naltrexone/bupropion extended release (NB) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of ≥30 or ≥27 kg m(-2) and ≥1 weight-related comorbidity (e.g. hypertension, type 2 diabetes and dyslipidaemia). In phase 3 clinical studies, nausea occurred in significantly higher proportions of subjects randomized to NB vs. placebo (PBO). In this pooled analysis of three phase 3, 56-week, PBO-controlled studies, we characterized nausea and weight loss in NB- and PBO-treated subjects without diabetes. Subjects receiving NB (n = 1778) lost significantly more weight than those receiving PBO (n = 1160). Weight change was not significantly different between subjects reporting and not reporting nausea in either treatment arm. Severity of nausea was mild to moderate in ≥95% of all cases. In the NB arm, the highest incidence of nausea onset (9%) was reported during week 1. The median duration of mild, moderate and severe nausea in subjects receiving NB was 14, 9 and 13 days, respectively. Our results demonstrate that nausea associated with NB is rarely severe, primarily occurs early in treatment and is not a contributor to weight loss.
Asunto(s)
Fármacos Antiobesidad/efectos adversos , Bupropión/efectos adversos , Naltrexona/efectos adversos , Náusea/inducido químicamente , Obesidad/tratamiento farmacológico , Sobrepeso/tratamiento farmacológico , Adulto , Fármacos Antiobesidad/uso terapéutico , Índice de Masa Corporal , Bupropión/uso terapéutico , Terapia Combinada/efectos adversos , Preparaciones de Acción Retardada/efectos adversos , Quimioterapia Combinada , Dislipidemias/etiología , Dislipidemias/prevención & control , Femenino , Humanos , Hipertensión/etiología , Hipertensión/prevención & control , Incidencia , Perdida de Seguimiento , Masculino , Naltrexona/uso terapéutico , Náusea/epidemiología , Náusea/fisiopatología , Obesidad/fisiopatología , Obesidad/terapia , Sobrepeso/fisiopatología , Sobrepeso/terapia , Pacientes Desistentes del Tratamiento , Índice de Severidad de la Enfermedad , Estados Unidos/epidemiología , Pérdida de Peso/efectos de los fármacosRESUMEN
MEF2 (myocyte-specific enhancer factor 2) is a MADS box transcription factor that is thought to be a key regulator of myogenesis in vertebrates. Mutations in the Drosophila homologue of the mef2 gene indicate that it plays a key role in regulating myogenesis in Drosophila. We show here that the Drosophila tropomyosin I (TmI) gene is a target gene for mef2 regulation. The TmI gene contains a proximal and a distal muscle enhancer within the first intron of the gene. We show that both enhancers contain a MEF2 binding site and that a mutation in the MEF2 binding site of either enhancer significantly reduces reporter gene expression in embryonic, larval, and adult somatic body wall muscles of transgenic flies. We also show that a high level of proximal enhancer-directed reporter gene expression in somatic muscles requires the cooperative activity of MEF2 and a cis-acting muscle activator region located within the enhancer. Thus, mef2 null mutant embryos show a significant reduction but not an elimination of TmI expression in the body wall myoblasts and muscle fibers that are present. Surprisingly, there is little effect in these mutants on TmI expression in developing visceral muscles and dorsal vessel (heart), despite the fact that MEF2 is expressed in these muscles in wild-type embryos, indicating that TmI expression is regulated differently in these muscles. Taken together, our results show that mef2 is a positive regulator of tropomyosin gene transcription that is necessary but not sufficient for high level expression in somatic muscle of the embryo, larva, and adult.